RETRACTED ARTICLE: Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma

Abstract

BackgroundMicroRNAs (miRNAs) play key roles in cancer development and progression. The purpose of the present study was to determine the expression levels of miR-133a and miR-539 in osteosarcoma patients and to further investigate the clinicopathological, and prognostic value of these miRNAs.MethodsThe expression levels of miR-133a and miR-539 were determined by qRT-PCR. Associations between miRNAs expressions and various clinicopathological characteristics were analyzed. Survival rate was determined with Kaplan–Meier and statistically analyzed with the log-rank method between groups. Survival data were evaluated through multivariate Cox regression analysisResultsOur findings revealed that the miR-133a expression was significantly decreased in clinical osteosarcoma tissues compared to adjacent normal bone tissues. The expression level of miR-539 was decreased in clinical osteosarcoma tissues as compared to those adjacent normal tissues. Low expressions of miR-133a and miR-539 were significantly association with advanced TNM stage (P = 0.002; P = 0.001), and metastasis or recurrence (P = 0.001; P = 0.01). Furthermore, Kaplan–Meier survival analysis and log-rank test showed that the low expressions of miR-133a and miR-539 were correlated with the reduced overall survival of osteosarcoma patients. Multivariate Cox proportional hazards model showed that decreased expressions of miR-133a and miR-539 (P = 0.007; P = 0.02), TNM stage (P = 0.001; P = 0.002), and metastasis or recurrence (P = 0.005; P = 0.026) were independent prognostic markers of overall survival of patients.ConclusionThese results suggest that decreased miR-133a and miR-539 expressions may participate in the progression of osteosarcoma. Together, these results showed that miR-133a and miR-539 may have their role in both progression and prognosis of osteosarcoma.

Retraction Note: Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma

“…The Editors-in-Chief and Publisher have retracted this article [1] because the scientific integrity of the content cannot be guaranteed. An investigation by the Publisher found it to be one of a group of articles we have identified as showing evidence suggestive of attempts to subvert the peer review and publication system to inappropriately obtain or allocate authorship.…”

Genetic and epigenetic drivers of neuroendocrine tumours (NET)

“…miR-133a has two subtypes, including miR-133a-1 and miR-133a-2, which are located on chromosomes 18q11.2, 20q13.33 (Mitchelson & Qin 2015). Low expression of miR-133a is associated with poor prognosis and promotion of tumorigenesis in several cancers (Kawakami et al 2012, Wu et al 2012, Wang et al 2014a,b, Lai et al 2015, Mirghasemi et al 2015. Several studies have confirmed that members of the miR-183/182/96 cluster are abnormally expressed in many tumours and are closely related to human cancers.…”

MicroRNA‑539 inhibits colorectal cancer progression by directly targeting SOX4

“…For example, a previous study demonstrated that miR-539 was downregulated in an osteosarcoma cell line compared with an osteoblast cell line (37). Mirghasemi et al (38) reported that miR-539 expression levels are relatively low in osteosarcoma tissues, and low expression of miR-539 was associated with TNM stage, metastasis and recurrence. In addition, Kaplan-Meier survival analysis and log-rank tests demonstrated that reduced miR-539 expression was associated with low overall survival in patients with osteosarcoma, and miR-539 was revealed to be an independent prognostic marker of overall survival in patients with osteosarcoma (38).…”

“…Mirghasemi et al (38) reported that miR-539 expression levels are relatively low in osteosarcoma tissues, and low expression of miR-539 was associated with TNM stage, metastasis and recurrence. In addition, Kaplan-Meier survival analysis and log-rank tests demonstrated that reduced miR-539 expression was associated with low overall survival in patients with osteosarcoma, and miR-539 was revealed to be an independent prognostic marker of overall survival in patients with osteosarcoma (38). Gu et al (39) reported that miR-539 expression is decreased in thyroid cancer tissues and cell lines.…”